The investigation examined various combinations of MSI (244 patients), KRAS mutation, and BRAF mutation: in contrast to the triple-negative group (MSI-negative, KRAS, and BRAF wild type), MSI-positive CRC with KRAS (p = 0.028) or BRAF (p = 0.017) mutations exhibited a notably improved prognosis. The gene discussed is KRAS; the disease is colorectal carcinoma.